Precision Neuroscience closed an oversubscribed $250M Series D at a valuation just above $1 billion, co-led by Pershing Square and the Ackman Oxman Institute. The round brings total funding to $430M and pushes Precision past a $1 billion valuation, placing it among the small group of BCI companies to reach unicorn status. Its Layer 7 interface has now been used in more than 100 patient procedures across 18 institutions. The funding will support further FDA review, clinical expansion, and commercialization.

Precision Neuroscience demonstrated thought-controlled cursor movement, gaming, and smartphone navigation in an able-bodied person, which it describes as the first time such control has been achieved without penetrating brain tissue. Its Layer 7 array rests on the cortical surface. Precision has tested Layer 7 in nearly 100 participants across 18 US medical centres, including people without paralysis undergoing epilepsy or tumour surgery. The company separately named BrainGate pioneer John Donoghue as a scientific advisor.